
Immunex sells Leukine to Schering AG
Executive Summary
Because of its pending takeover by Amgen, Immunex (immune system treatments) is selling Schering AG its growth factor Leukine for about $380mm in cash, plus developmental milestones (also in cash).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice